PODCAST
Kidney Stones, Scotland's New Drug, and Menopause Goes to Work
July 16, 2026·8:23·Episode 81
Quick Summary
A new study published in the NAMS journal Menopause links premature menopause to significantly higher risk of kidney stone disease across two large datasets, including the UK Biobank. Scotland has approved the first non-hormonal menopause drug, expanding options for women who can't or won't use hormone therapy. And Washington State's governor has signed an executive order requiring workplace support for employees experiencing perimenopause and menopause.
Kidney Stones, Scotland's New Drug, and Menopause Goes to Work
0:000:00
Key Takeaways
- ✦Women who experienced premature menopause (before age 40) showed a consistently higher risk of kidney stone disease across both UK Biobank and NHANES cohorts, with the association holding up across multiple analytical methods.
- ✦Hormone therapy did not meaningfully modify the kidney stone risk, suggesting the connection may be driven by genetic or metabolic factors rather than estrogen loss alone.
- ✦Scotland has approved a non-hormonal drug for menopause symptoms — significant news for the substantial number of women who cannot use or choose not to use HRT.
- ✦Washington Governor Bob Ferguson signed an executive order directing state agencies to support employees experiencing perimenopause and menopause in the workplace, making Washington one of the more concrete US policy actors on this issue.
- ✦The kidney stone–premature menopause link is a reminder that early menopause has downstream health consequences beyond the cardiovascular and bone density risks that get most of the attention.
Sources & References
Hot Flasher provides informational content only and does not constitute medical advice. Always consult a qualified healthcare provider for medical concerns.